Purushottamachar Puranik - Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenograf...

Document created by Purushottamachar Puranik on Aug 22, 2014
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

  Bioorg Med Chem. 2008   Mar 15;16(6):3352-60. Epub 2007 Dec 8.

  Abstract:

  We have developed new, simple, and efficient procedures for the   synthesis of two promising histone deacetylase inhibitors (HDIs),   CI-994, (N-(2-aminophenyl)-4-acetylaminobenzamide), and MS-275   (N-(2-aminophenyl)4-[N-(pyridine-3-yl-methoxycarbonyl)aminomethyl]benzamide)   from commercially available acetamidobenzoic acid and   3-(hydroxymethyl)pyridine, respectively. The procedures provide   CI-994 and MS-275 in 80% and 72% overall yields, respectively. We   found that the combination of four HDIs (CI-994, MS-275, SAHA,   and TSA) with retinoids all-trans-retinoic acid (ATRA) or   13-cis-retinoic acid (13-CRA) or our atypical retinoic acid   metabolism blocking agents (RAMBAs) 1 (VN/14-1) or 2 (VN/66-1)   produced synergistic anti-neoplastic activity on human LNCaP   prostate cancer cells. The combination of 2 and SAHA induced G1   and G2/M cell cycle arrest and a decrease in the S phase in LNCaP   cells. 2+SAHA treatment effectively down-regulated cyclin D1 and   cdk4, and up-regulated pro-differentiation markers cytokeratins   8/18 and pro-apoptotic Bad and Bax. Following subcutaneous   administration, 2, SAHA or 2+SAHA were well tolerated and caused   significant suppression/regression of tumor growth compared with   control. These results demonstrate that compound 2 and its   combination with SAHA are potentially useful agents that warrant   further preclinical development for treatment of prostate cancer.

 
   
      PMID:18166465    
 

  Address (URL): http://www.ncbi.nlm.nih.gov/pubmed/18166465

 

Attachments

    Outcomes